7.85 USD
+0.13 (+1.68%)
7.85 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to GYRE. GYRE was compared to 533 industry peers in the Biotechnology industry. GYRE has an excellent financial health rating, but there are some minor concerns on its profitability. GYRE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
GYRE had positive earnings in the past year.
In the past year GYRE had a positive cash flow from operations.
GYRE had negative earnings in 4 of the past 5 years.
In the past 5 years GYRE reported 4 times negative operating cash flow.
1.2 Ratios
GYRE has a better Return On Assets (4.17%) than 90.81% of its industry peers.
GYRE has a better Return On Equity (6.53%) than 91.93% of its industry peers.
The Return On Invested Capital of GYRE (6.46%) is better than 92.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.17% | ||
| ROE | 6.53% | ||
| ROIC | 6.46% |
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 6.20%, GYRE belongs to the best of the industry, outperforming 90.99% of the companies in the same industry.
GYRE has a better Operating Margin (11.22%) than 92.31% of its industry peers.
GYRE has a better Gross Margin (95.48%) than 95.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.22% | ||
| PM (TTM) | 6.2% | ||
| GM | 95.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GYRE is destroying value.
Compared to 1 year ago, GYRE has more shares outstanding
GYRE has more shares outstanding than it did 5 years ago.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.43 indicates that GYRE is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 8.43, GYRE is doing good in the industry, outperforming 79.92% of the companies in the same industry.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.43 |
ROIC/WACC0.75
WACC8.64%
2.3 Liquidity
GYRE has a Current Ratio of 6.19. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
GYRE has a Current ratio of 6.19. This is in the better half of the industry: GYRE outperforms 65.29% of its industry peers.
A Quick Ratio of 5.64 indicates that GYRE has no problem at all paying its short term obligations.
GYRE's Quick ratio of 5.64 is fine compared to the rest of the industry. GYRE outperforms 61.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.64 |
3. Growth
3.1 Past
GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 128.26%, which is quite impressive.
The Revenue for GYRE has decreased by -43.94% in the past year. This is quite bad
GYRE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.34% yearly.
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%
3.2 Future
Based on estimates for the next years, GYRE will show a very strong growth in Earnings Per Share. The EPS will grow by 24.13% on average per year.
The Revenue is expected to grow by 17.75% on average over the next years. This is quite good.
EPS Next Y-66.54%
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
EPS Next 5Y24.13%
Revenue Next Year-0.74%
Revenue Next 2Y14.96%
Revenue Next 3Y6.86%
Revenue Next 5Y17.75%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 60.38, the valuation of GYRE can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of GYRE indicates a rather cheap valuation: GYRE is cheaper than 90.24% of the companies listed in the same industry.
GYRE is valuated expensively when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 41.23, the valuation of GYRE can be described as expensive.
90.43% of the companies in the same industry are more expensive than GYRE, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.12, GYRE is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.38 | ||
| Fwd PE | 41.23 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GYRE is valued cheaply inside the industry as 90.99% of the companies are valued more expensively.
89.49% of the companies in the same industry are more expensive than GYRE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 528.55 | ||
| EV/EBITDA | 44.15 |
4.3 Compensation for Growth
A cheap valuation may be justified as GYRE's earnings are expected to decrease with -39.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
5. Dividend
5.1 Amount
No dividends for GYRE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.85
+0.13 (+1.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.78%
Inst Owner Change-9.21%
Ins Owners7.04%
Ins Owner Change0%
Market Cap713.02M
Revenue(TTM)107.27M
Net Income(TTM)6.65M
Analysts84.44
Price Target18.36 (133.89%)
Short Float %13.21%
Short Ratio18.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)194.08%
EPS beat(4)1
Avg EPS beat(4)13.67%
Min EPS beat(4)-102.82%
Max EPS beat(4)194.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.9%
Min Revenue beat(2)-14.79%
Max Revenue beat(2)-9.01%
Revenue beat(4)1
Avg Revenue beat(4)-7.84%
Min Revenue beat(4)-23.85%
Max Revenue beat(4)16.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.26%
PT rev (3m)-10%
EPS NQ rev (1m)36.35%
EPS NQ rev (3m)66.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.89%
Revenue NQ rev (1m)-1.3%
Revenue NQ rev (3m)-2.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.38 | ||
| Fwd PE | 41.23 | ||
| P/S | 6.65 | ||
| P/FCF | 528.55 | ||
| P/OCF | 183.91 | ||
| P/B | 7 | ||
| P/tB | 7.35 | ||
| EV/EBITDA | 44.15 |
EPS(TTM)0.13
EY1.66%
EPS(NY)0.19
Fwd EY2.43%
FCF(TTM)0.01
FCFY0.19%
OCF(TTM)0.04
OCFY0.54%
SpS1.18
BVpS1.12
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.17% | ||
| ROE | 6.53% | ||
| ROCE | 8.39% | ||
| ROIC | 6.46% | ||
| ROICexc | 11.19% | ||
| ROICexgc | 11.89% | ||
| OM | 11.22% | ||
| PM (TTM) | 6.2% | ||
| GM | 95.48% | ||
| FCFM | 1.26% |
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 110.59% | ||
| Cap/Sales | 2.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 27.08% | ||
| Profit Quality | 20.28% | ||
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.64 | ||
| Altman-Z | 8.43 |
F-Score5
WACC8.64%
ROIC/WACC0.75
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
EPS Next Y-66.54%
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
EPS Next 5Y24.13%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%
Revenue Next Year-0.74%
Revenue Next 2Y14.96%
Revenue Next 3Y6.86%
Revenue Next 5Y17.75%
EBIT growth 1Y-72.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.21%
EBIT Next 3Y-33.44%
EBIT Next 5YN/A
FCF growth 1Y110.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.93%
OCF growth 3YN/A
OCF growth 5YN/A
GYRE THERAPEUTICS INC / GYRE FAQ
What is the fundamental rating for GYRE stock?
ChartMill assigns a fundamental rating of 6 / 10 to GYRE.
What is the valuation status of GYRE THERAPEUTICS INC (GYRE) stock?
ChartMill assigns a valuation rating of 4 / 10 to GYRE THERAPEUTICS INC (GYRE). This can be considered as Fairly Valued.
Can you provide the profitability details for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) has a profitability rating of 5 / 10.
What are the PE and PB ratios of GYRE THERAPEUTICS INC (GYRE) stock?
The Price/Earnings (PE) ratio for GYRE THERAPEUTICS INC (GYRE) is 60.38 and the Price/Book (PB) ratio is 7.
What is the earnings growth outlook for GYRE THERAPEUTICS INC?
The Earnings per Share (EPS) of GYRE THERAPEUTICS INC (GYRE) is expected to decline by -66.54% in the next year.